阿霉素与伊达比星治疗成人急性髓性白血病的疗效比较
Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia.
作者信息
Sherif Hemat Afifi, Magdy Ahmed, Elshesheni Heba Anees, Ramadan Sherein Mahmoud, Rashed Reham A
机构信息
Nasr Hospital, Cairo, Egypt.
National Cancer Institute, Cairo, Egypt.
出版信息
Leuk Res Rep. 2021 Oct 7;16:100272. doi: 10.1016/j.lrr.2021.100272. eCollection 2021.
PURPOSE
The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients.
PATIENTS AND METHODS
This retrospective study included 143 patients with de novo AML. All patients received full dose of standard induction therapy (3 + 7) using anthracyclines (doxorubicin or idarubicin) and cytarabine.
RESULTS
The studied groups had comparable CR. No significant differences were noted between the studied groups regarding DFS and OS. The DXR group had significantly lower cost in comparison to IDA group.
CONCLUSIONS
Idarubicin doesn't have a clear advantage over doxorubicin in treatment of AML.
目的
本研究旨在比较伊达比星与多柔比星联合阿糖胞苷作为初治急性髓系白血病（AML）患者诱导治疗的疗效。
患者与方法
这项回顾性研究纳入了143例初发AML患者。所有患者均接受了使用蒽环类药物（多柔比星或伊达比星）和阿糖胞苷的标准全剂量诱导治疗（3+7）。
结果
研究组的完全缓解率相当。在无病生存期（DFS）和总生存期（OS）方面，研究组之间未观察到显著差异。与伊达比星组相比，多柔比星组的费用显著更低。
结论
在AML治疗中，伊达比星并不比多柔比星具有明显优势。
Zotero 插件